Freenome, Inc. — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Freenome announced launch of SimpleScreen Lung (LDT, not FDA-approved), a blood-based lung cancer screening test showing 85% sensitivity at 50% specificity and 99.8% NPV in an independent cohort of 172 cases and 436 controls. The test can be ordered standalone or combined with FDA-approved SimpleScreen CRC in a single blood draw, targeting adults 50-80 with ≥20 pack-year smoking history. Abbott retains exclusive commercial rights to standalone SimpleScreen CRC; no financial terms, revenue projections, or partnership changes disclosed.
Why this rating
Portfolio expansion with clinical validation is operationally positive but modest relative to $91.6M market cap. No FDA approval, revenue impact, or commercialization timeline disclosed. Moderate near-term significance.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.